Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Clinical Thyroidology / Review

Free Access

Hypothyroidism and Depression

Dayan C.M.a · Panicker V.b

Author affiliations

aCardiff University School of Medicine, Heath Park, Cardiff, UK; bDepartment of Endocrinology, Sir Charles Gairdner Hospital, Nedlands, W.A., Australia

Corresponding Author

Colin M. Dayan, MA, FRCP, PhD

Cardiff University School of Medicine

Heath Park, Cardiff CF14 4XN (UK)

E-Mail DayanCM@cardiff.ac.uk

Related Articles for ""

Eur Thyroid J 2013;2:168-179

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Background: A relationship between hypothyroidism and depression has been assumed for many years; however, the true nature of this association has been difficult to define with many conflicting studies. In recent years, our knowledge in this area has increased significantly with large cohort studies and genetically driven studies being published. Objectives: We reviewed the literature on thyroid function and depression to determine if this relationship has been clarified. Methods: We performed a search on the Pubmed database using the terms ‘thyroid' and ‘mental health', ‘depression' and ‘well-being'. Results: Large epidemiological studies generally suggest no association between thyroid function and depression in subjects without thyroid disease. Subjects on thyroxine have poorer psychological well-being than subjects with no thyroid disease even if biochemically euthyroid, they also show an association between thyroid function and well-being. Whilst there is some early evidence that genetic factors can influence well-being on thyroxine and response to combination therapy, there is also evidence to suggest that much morbidity on thyroxine may be due to initial misdiagnosis and mis-attribution of symptoms. Conclusion: Despite the large number of studies, the relationship between thyroid function and depression remains poorly defined. Clarification of the proportion of subjects on thyroxine incorrectly may assist the large (perhaps genetically driven) studies needed to move forward in this area, as it is expected that they cloud the results.

© 2013 European Thyroid Association Published by S. Karger AG, Basel


  1. Hetzel BS, Chavadej J, Potter BJ: The brain in iodine deficiency. Neuropathol Appl Neurobiol 1988;14:93-104.
  2. Chaouki ML, Maoui R, Benmiloud M: Comparative study of neurological and myxoedematous cretinism associated with severe iodine deficiency. Clin Endocrinol (Oxf) 1988;28:399-408.
  3. Friesema EC, Grueters A, Biebermann H, Krude H, von Moers A, Reeser M, Barrett TG, Mancilla EE, Svensson J, Kester MH, Kuiper GG, Balkassmi S, Uitterlinden AG, Koehrle J, Rodien P, Halestrap AP, Visser TJ: Association between mutations in a thyroid hormone transporter and severe X-linked psychomotor retardation. Lancet 2004;364:1435-1437.
  4. Schwartz CE, May MM, Carpenter NJ, Rogers RC, Martin J, Bialer MG, Ward J, Sanabria J, Marsa S, Lewis JA, Echeverri R, Lubs HA, Voeller K, Simensen RJ, Stevenson RE: Allan-Herndon-Dudley syndrome and the monocarboxylate transporter 8 (MCT8) gene. Am J Hum Genet 2005;77:41-53.
  5. LaFranchi S: Congenital hypothyroidism: etiologies, diagnosis, and management. Thyroid 1999;9:735-740.
  6. Gruters A, Krude H: Detection and treatment of congenital hypothyroidism. Nat Rev 2012;8:104-113.
  7. Heuer H: The importance of thyroid hormone transporters for brain development and function. Best Pract Res Clin Endocrinol Metab 2007;21:265-276.
  8. Kirkegaard C, Faber J: The role of thyroid hormones in depression. Eur J Endocrinol 1998;138:1-9.
  9. Henley WN, Koehnle TJ: Thyroid hormones and the treatment of depression: An examination of basic hormonal actions in the mature mammalian brain. Synapse 1997;27:36-44.
  10. Bauer M, Heinz A, Whybrow PC: Thyroid hormones, serotonin and mood: Of synergy and significance in the adult brain. Mol Psychiatry 2002;7:140-156.
  11. Whybrow PC, Prange AJ Jr: A hypothesis of thyroid-catecholamine-receptor interaction. Its relevance to affective illness. Arch Gen Psychiatry 1981;38:106-113.
  12. Gordon JT, Kaminski DM, Rozanov CB, Dratman MB: Evidence that 3,3′,5-triiodothyronine is concentrated in and delivered from the locus coeruleus to its noradrenergic targets via anterograde axonal transport. Neuroscience 1999;93:943-954.
  13. Mason GA, Bondy SC, Nemeroff CB, Walker CH, Prange AJ Jr: The effects of thyroid state on beta-adrenergic and serotonergic receptors in rat brain. Psychoneuroendocrinology 1987;12:261-270.
  14. Engum A, Bjoro T, Mykletun A, Dahl AA: An association between depression, anxiety and thyroid function - a clinical fact or an artefact? Acta Psychiatr Scand 2002;106:27-34.
  15. Panicker V, Evans J, Bjoro T, Asvold BO, Dayan CM, Bjerkeset O: A paradoxical difference in relationship between anxiety, depression and thyroid function in subjects on and not on T4: findings from the Hunt study. Clin Endocrinol (Oxf) 2009;71:574-580.
  16. Forman-Hoffman V, Philibert RA: Lower TSH and higher T4 levels are associated with current depressive syndrome in young adults. Acta Psychiatr Scand 2006;114:132-139.
  17. Williams MD, Harris R, Dayan CM, Evans J, Gallacher J, Ben-Shlomo Y: Thyroid function and the natural history of depression: findings from the Caerphilly Prospective Study (CAPS) and a meta-analysis. Clin Endocrinol 2009;70:484-492.
  18. Roberts LM, Pattison H, Roalfe A, Franklyn J, Wilson S, Hobbs FD, Parle JV: Is subclinical thyroid dysfunction in the elderly associated with depression or cognitive dysfunction? Ann Intern Med 2006;145:573-581.
  19. Almeida OP, Alfonso H, Flicker L, Hankey G, Chubb SA, Yeap BB: Thyroid hormones and depression: the health in men study. Am J Geriatr Psychiatry 2011;19:763-770.
  20. Guimaraes JM, de Souza Lopes C, Baima J, Sichieri R: Depression symptoms and hypothyroidism in a population-based study of middle-aged Brazilian women. J Affect Disord 2009;117:120-123.
  21. Gulseren S, Gulseren L, Hekimsoy Z, Cetinay P, Ozen C, Tokatlioglu B: Depression, anxiety, health-related quality of life, and disability in patients with overt and subclinical thyroid dysfunction. Arch Med Res 2006;37:133-139.
  22. Bono G, Fancellu R, Blandini F, Santoro G, Mauri M: Cognitive and affective status in mild hypothyroidism and interactions with L-thyroxine treatment. Acta Neurol Scand 2004;110:59-66.
  23. van de Ven AC, Muntjewerff JW, Netea-Maier RT, de Vegt F, Ross HA, Sweep FC, Kiemeney LA, Vos PE, Buitelaar JK, Hermus AR, den Heijer M, Janzing JG: Association between thyroid function, thyroid autoimmunity, and state and trait factors of depression. Acta Psychiatr Scand 2012;126:377-384.
  24. Philibert RA, Beach SR, Gunter TD, Todorov AA, Brody GH, Vijayendran M, Elliott L, Hollenbeck N, Russell D, Cutrona C: The relationship of deiodinase 1 genotype and thyroid function to lifetime history of major depression in three independent populations. Am J Med Genetics B 2011;156B:593-599.
  25. Pop VJ, Maartens LH, Leusink G, van Son MJ, Knottnerus AA, Ward AM, Metcalfe R, Weetman AP: Are autoimmune thyroid dysfunction and depression related? J Clin Endocrinol Metab 1998;83:3194-3197.
  26. Kirim S, Keskek SO, Koksal F, Haydardedeoglu FE, Bozkirli E, Toledano Y: Depression in patients with euthyroid chronic autoimmune thyroiditis. Endocr J 2012;59:705-708.
  27. Engum A, Bjoro T, Mykletun A, Dahl AA: Thyroid autoimmunity, depression and anxiety; are there any connections? An epidemiological study of a large population. J Psychosom Res 2005;59:263-268.
  28. Saravanan P, Chau WF, Roberts N, Vedhara K, Greenwood R, Dayan CM: Psychological well-being in patients on ‘adequate' doses of L-thyroxine: results of a large, controlled community-based questionnaire study. Clin Endocrinol (Oxf) 2002;57:577-585.
  29. Saravanan P, Visser TJ, Dayan CM: Psychological well-being correlates with free thyroxine but not free 3,5,3′-triiodothyronine levels in patients on thyroid hormone replacement. J Clin Endocrinol Metab 2006;91:3389-3393.
  30. Wekking EM, Appelhof BC, Fliers E, Schene AH, Huyser J, Tijssen JG, Wiersinga WM: Cognitive functioning and well-being in euthyroid patients on thyroxine replacement therapy for primary hypothyroidism. Eur J Endocrinol 2005;153:747-753.
  31. Walsh JP, Ward LC, Burke V, Bhagat CI, Shiels L, Henley D, Gillett MJ, Gilbert R, Tanner M, Stuckey BG: Small changes in thyroxine dosage do not produce measurable changes in hypothyroid symptoms, well-being, or quality of life: results of a double-blind, randomized clinical trial. J Clin Endocrinol Metab 2006;91:2624-2630.
  32. Samuels MH, Schuff KG, Carlson NE, Carello P, Janowsky JS: Health status, psychological symptoms, mood, and cognition in L-thyroxine-treated hypothyroid subjects. Thyroid 2007;17:249-258.
  33. Kramer CK, von Muhlen D, Kritz-Silverstein D, Barrett-Connor E: Treated hypothyroidism, cognitive function, and depressed mood in old age: The Rancho Bernardo study. Eur J Endocrinol 2009;161:917-921.
  34. Bould H, Panicker V, Kessler D, Durant C, Lewis G, Dayan C, Evans J: Investigation of thyroid dysfunction in general practice is more likely in patients with high psychological morbidity. Fam Pract 2012;29:163-167.
  35. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC: The Colorado Thyroid Disease Prevalence study. Arch Intern Med 2000;160:526-534.
  36. Leese GP, Flynn RV, Jung RT, Macdonald TM, Murphy MJ, Morris AD: Increasing prevalence and incidence of thyroid disease in Tayside, Scotland: the thyroid epidemiology audit and research study (tears). Clin Endocrinol (Oxf) 2008;68:311-316.
  37. Taylor P, Iqbal A, Minassian C, Sayers A, Draman M, Greenwood R, Hamilton W, Okosieme O, Panicker V, Thomas S, Dayan C: Falling threshold for treatment of borderline elevated TSH levels - balancing benefits and risks: evidence from a large community based study. JAMA Intern Med 2013, in press.
  38. Jorde R, Waterloo K, Storhaug H, Nyrnes A, Sundsfjord J, Jenssen TG: Neuropsychological function and symptoms in subjects with subclinical hypothyroidism and the effect of thyroxine treatment. J Clin Endocrinol Metab 2006;91:145-153.
  39. Jaeschke R, Guyatt G, Gerstein H, Patterson C, Molloy W, Cook D, Harper S, Griffith L, Carbotte R: Does treatment with L-thyroxine influence health status in middle-aged and older adults with subclinical hypothyroidism? J Gen Intern Med 1996;11:744-749.
  40. Kong WM, Sheikh MH, Lumb PJ, Naoumova RP, Freedman DB, Crook M, Dore CJ, Finer N: A 6-month randomized trial of thyroxine treatment in women with mild subclinical hypothyroidism. Am J Med 2002;112:348-354.
  41. Meier C, Staub JJ, Roth CB, Guglielmetti M, Kunz M, Miserez AR, Drewe J, Huber P, Herzog R, Muller B: TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel Thyroid study). J Clin Endocrinol Metab 2001;86:4860-4866.
  42. Baldini M, Colasanti A, Orsatti A, Airaghi L, Mauri MC, Cappellini MD: Neuropsychological functions and metabolic aspects in subclinical hypothyroidism: the effects of L-thyroxine. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:854-859.
  43. Escobar-Morreale HF, Obregon MJ, Escobar del Rey F, Morreale de Escobar G: Replacement therapy for hypothyroidism with thyroxine alone does not ensure euthyroidism in all tissues, as studied in thyroidectomized rats. J Clin Invest 1995;96:2828-2838.
  44. Escobar-Morreale HF, del Rey FE, Obregon MJ, de Escobar GM: Only the combined treatment with thyroxine and triiodothyronine ensures euthyroidism in all tissues of the thyroidectomized rat. Endocrinology 1996;137:2490-2502.
  45. Bunevicius R, Kazanavicius G, Zalinkevicius R, Prange AJ Jr: Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl J Med 1999;340:424-429.
  46. Bunevicius R, Jakubonien N, Jurkevicius R, Cernicat J, Lasas L, Prange AJ Jr: Thyroxine vs. thyroxine plus triiodothyronine in treatment of hypothyroidism after thyroidectomy for Graves' disease. Endocrine 2002;18:129-133.
  47. Sawka AM, Gerstein HC, Marriott MJ, MacQueen GM, Joffe RT: Does a combination regimen of thyroxine (T4) and 3,5,3′-triiodothyronine improve depressive symptoms better than T4 alone in patients with hypothyroidism? Results of a double-blind, randomized, controlled trial. J Clin Endocrinol Metab 2003;88:4551-4555.
  48. Clyde PW, Harari AE, Getka EJ, Shakir KM: Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial. Jama 2003;290:2952-2958.
  49. Walsh JP, Shiels L, Lim EM, Bhagat CI, Ward LC, Stuckey BG, Dhaliwal SS, Chew GT, Bhagat MC, Cussons AJ: Combined thyroxine/liothyronine treatment does not improve well-being, quality of life, or cognitive function compared to thyroxine alone: A randomized controlled trial in patients with primary hypothyroidism. J Clin Endocrinol Metab 2003;88:4543-4550.
  50. Siegmund W, Spieker K, Weike AI, Giessmann T, Modess C, Dabers T, Kirsch G, Sanger E, Engel G, Hamm AO, Nauck M, Meng W: Replacement therapy with levothyroxine plus triiodothyronine (bioavailable molar ratio 14:1) is not superior to thyroxine alone to improve well-being and cognitive performance in hypothyroidism. Clin Endocrinol (Oxf) 2004;60:750-757.
  51. Appelhof BC, Fliers E, Wekking EM, Schene AH, Huyser J, Tijssen JG, Endert E, van Weert HC, Wiersinga WM: Combined therapy with levothyroxine and liothyronine in two ratios, compared with levothyroxine monotherapy in primary hypothyroidism: a double-blind, randomized, controlled clinical trial. J Clin Endocrinol Metab 2005;90:2666-2674.
  52. Escobar-Morreale HF, Botella-Carretero JI, Gomez-Bueno M, Galan JM, Barrios V, Sancho J: Thyroid hormone replacement therapy in primary hypothyroidism: a randomized trial comparing L-thyroxine plus liothyronine with L-thyroxine alone. Ann Intern Med 2005;142:412-424.
  53. Levitt JA, Silverberg J: T4 plus T3 for hypothyroidism: a double-blind comparison with usual T4. Proc of the 74th Ann Meet American Thyroid Association, Los Angeles, 2002.
  54. Rodriguez T, Lavis VR, Meininger JC, Kapadia AS, Stafford LF: Substitution of liothyronine at a 1:5 ratio for a portion of levothyroxine: effect on fatigue, symptoms of depression, and working memory versus treatment with levothyroxine alone. Endocr Pract 2005;11:223-233.
    External Resources
  55. Saravanan P, Simmons DJ, Greenwood R, Peters TJ, Dayan CM: Partial substitution of thyroxine (T4) with tri-iodothyronine in patients on T4 replacement therapy: results of a large community-based randomized controlled trial. J Clin Endocrinol Metab 2005;90:805-812.
  56. Grozinsky-Glasberg S, Fraser A, Nahshoni E, Weizman A, Leibovici L: Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 2006;91:2592-2599.
  57. Ma C, Xie J, Huang X, Wang G, Wang Y, Wang X, Zuo S: Thyroxine alone or thyroxine plus triiodothyronine replacement therapy for hypothyroidism. Nucl Med Commun 2009;30:586-593.
  58. Joffe RT, Brimacombe M, Levitt AJ, Stagnaro-Green A: Treatment of clinical hypothyroidism with thyroxine and triiodothyronine: a literature review and metaanalysis. Psychosomatics 2007;48:379-384.
  59. Nygaard B, Jensen EW, Kvetny J, Jarlov A, Faber J: Effect of combination therapy with thyroxine (T4) and 3,5,3′-triiodothyronine versus T4 monotherapy in patients with hypothyroidism, a double-blind, randomised cross-over study. Eur J Endocrinol 2009;161:895-902.
  60. Panicker V, Saravanan P, Vaidya B, Evans J, Hattersley AT, Frayling TM, Dayan CM: Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J Clin Endocrinol Metab 2009;94:1623-1629.
  61. van der Deure WM, Appelhof BC, Peeters RP, Wiersinga WM, Wekking EM, Huyser J, Schene AH, Tijssen JG, Hoogendijk WJ, Visser TJ, Fliers E: Polymorphisms in the brain-specific thyroid hormone transporter OATP1C1 are associated with fatigue and depression in hypothyroid patients. Clin Endocrinol (Oxf) 2008;69:804-811.
  62. Parle JV, Franklyn JA, Cross KW, Jones SR, Sheppard MC: Thyroxine prescription in the community: serum thyroid stimulating hormone level assays as an indicator of undertreatment or overtreatment. Br J Gen Pract 1993;43:107-109.
    External Resources
  63. Flynn RW, Bonellie SR, Jung RT, MacDonald TM, Morris AD, Leese GP: Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab 2010;95:186-193.
  64. Altshuler LL, Bauer M, Frye MA, Gitlin MJ, Mintz J, Szuba MP, Leight KL, Whybrow PC: Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am J Psychiatry 2001;158:1617-1622.
  65. Aronson R, Offman HJ, Joffe RT, Naylor CD: Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry 1996;53:842-848.
  66. Cooper-Kazaz R, Lerer B: Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors. Int J Neuropsychopharmacol 2008;11:685-699.
  67. Garlow SJ, Dunlop BW, Ninan PT, Nemeroff CB: The combination of triiodothyronine (t3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorder. J Psychiatr Res 2012;46:1406-1413.
  68. Appelhof BC, Brouwer JP, van Dyck R, Fliers E, Hoogendijk WJ, Huyser J, Schene AH, Tijssen JG, Wiersinga WM: Triiodothyronine addition to paroxetine in the treatment of major depressive disorder. J Clin Endocrinol Metab 2004;89:6271-6276.
  69. Cooper-Kazaz R, Apter JT, Cohen R, Karagichev L, Muhammed-Moussa S, Grupper D, Drori T, Newman ME, Sackeim HA, Glaser B, Lerer B: Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 2007;64:679-688.
  70. Kelly T, Lieberman DZ: The use of triiodothyronine as an augmentation agent in treatment-resistant bipolar ii and bipolar disorder nos. J Affect Disord 2009;116:222-226.
  71. Stancer HC, Persad E: Treatment of intractable rapid-cycling manic-depressive disorder with levothyroxine. Clinical observations. Arch Gen Psychiatry 1982;39:311-312.
  72. Bauer M, Berghofer A, Bschor T, Baumgartner A, Kiesslinger U, Hellweg R, Adli M, Baethge C, Muller-Oerlinghausen B: Supraphysiological doses of L-thyroxine in the maintenance treatment of prophylaxis-resistant affective disorders. Neuropsychopharmacology 2002;27:620-628.
  73. Cooper-Kazaz R, van der Deure WM, Medici M, Visser TJ, Alkelai A, Glaser B, Peeters RP, Lerer B: Preliminary evidence that a functional polymorphism in type 1 deiodinase is associated with enhanced potentiation of the antidepressant effect of sertraline by triiodothyronine. J Affect Disord 2009;116:113-116.
  74. Grabe HJ, Volzke H, Ludemann J, Wolff B, Schwahn C, John U, Meng W, Freyberger HJ: Mental and physical complaints in thyroid disorders in the general population. Acta Psychiatr Scand 2005;112:286-293.
  75. de Jongh RT, Lips P, van Schoor NM, Rijs KJ, Deeg DJ, Comijs HC, Kramer MH, Vandenbroucke JP, Dekkers OM: Endogenous subclinical thyroid disorders, physical and cognitive function, depression, and mortality in older individuals. Eur J Endocrinol 2011;165:545-554.
  76. Kritz-Silverstein D, Schultz ST, Palinska LA, Wingard DL, Barrett-Connor E: The association of thyroid stimulating hormone levels with cognitive function and depressed mood: the Rancho Bernardo study. J Nutr Health Aging 2009;13:317-321.
  77. Gussekloo J, van Exel E, de Craen AJ, Meinders AE, Frolich M, Westendorp RG: Thyroid status, disability and cognitive function, and survival in old age. JAMA 2004;292:2591-2599.
  78. Kim JM, Stewart R, Kim SY, Bae KY, Yang SJ, Kim SW, Shin IS, Yoon JS: Thyroid stimulating hormone, cognitive impairment and depression in an older Korean population. Psychiatry Invest 2010;7:264-269.
  79. Frey A, Lampert A, Dietz K, Striebich S, Locher C, Fedorenko O, Mohle R, Gallinat J, Lang F, Lang UE: Thyrotropin serum concentrations in healthy volunteers are associated with depression-related personality traits. Neuropsychobiology 2007;56:123-126.
  80. van Boxtel MP, Menheere PP, Bekers O, Hogervorst E, Jolles J: Thyroid function, depressed mood, and cognitive performance in older individuals: the Maastricht aging study. Psychoneuroendocrinology 2004;29:891-898.

Article / Publication Details

First-Page Preview
Abstract of Clinical Thyroidology / Review

Received: March 08, 2013
Accepted: June 06, 2013
Published online: August 27, 2013
Issue release date: September 2013

Number of Print Pages: 12
Number of Figures: 4
Number of Tables: 2

ISSN: 2235-0640 (Print)
eISSN: 2235-0802 (Online)

For additional information: https://www.karger.com/ETJ

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.